Eliglustat | B1217

Eliglustat is a potent and specific inhibitor of glucosylceramide synthase. Eliglustat is a new promising substrate reduction therapy (SRT) for Gaucher disease (GD). Eliglustat works by inhibiting UDP-glucosylceramide synthase, the first enzyme that catalyzes the biosynthesis of glycosphingolipids, thus reducing the load of glucosylceramide influx into the lysosome.

Eliglustat is a potent and specific inhibitor of glucosylceramide synthase. Eliglustat is a new promising substrate reduction therapy (SRT) for Gaucher disease (GD). Eliglustat works by inhibiting UDP-glucosylceramide synthase, the first enzyme that catalyzes the biosynthesis of glycosphingolipids, thus reducing the load of glucosylceramide influx into the lysosome.

B1217 | Eliglustat DataSheet

Alternate Name/Synonyms: N-((1R,2R)-1-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-1-hydroxy-3-(pyrrolidin-1-yl)propan-2-yl)octanamide hemi((2R,3R)-2,3-dihydroxysuccinate); Genz99067

Appearance: Crystalline solid

Formulation: N/A

CAS Number: 491833-29-5

Structure Available?: Yes

Peptide sequence: N/A

Salt Form: No

Molecular Formula: C₂₃H₃₆N₂O

Molecular Weight: 404.54

Cell-Permeable?: Yes

Purity: ≥98% by HPLC

Solubilities: DMSO(>5 mg/ml)

Handling: Protect from air and light

Country of Origin: USA

Tag Line: A potent and specific glucosylceramide synthase inhibitor

MDL Number: N/A

PubChem CID: 23652731

SMILES: CCCCCCCC(=O)NC(CN1CCCC1)C(C2=CC3=C(C=C2)OCCO3)O

InChi: InChI=1S/C23H36N2O4/c1-2-3-4-5-6-9-22(26)24-19(17-25-12-7-8-13-25)23(27)18-10-11-20-21(16-18)29-15-14-28-20/h10-11,16,19,23,27H,2-9,12-15,17H2,1H3,(H,24,26)/t19-,23-/m1/s1

InChi Key: FJZZPCZKBUKGGU-AUSIDOKSSA-N